ArticleJournal of studies on alcohol and drugs2019
Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
Article in Journal of studies on alcohol and drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis.Psychopharmacology bulletin · 2026Pooled it
- Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis.Drug and alcohol dependence · 2025Pooled it
- Correlates of post-hospitalization naltrexone adherence for alcohol use disorder.Drug and alcohol dependence · 2024Trial
- Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.Alcoholism, clinical and experimental research · 2021Trial
- Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors.Addiction (Abingdon, England) · 2026Observational
- Article
- Exploring the lived experience of alcohol use disorder patients in accessing hospitalized treatment care in Rwanda.Discover mental health · 2026Article
- Pharmacists expand access to contingency management in patients with substance use disorders.The mental health clinician · 2026Article
- Trends, timing, and predictors of alcohol use disorder treatment among US adult cancer survivors.Journal of internal medicine · 2025Article
- A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder.Brain sciences · 2025Review
- Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease.Alimentary pharmacology & therapeutics · 2025Article
- Treatment patterns and healthcare resource use among veterans initiating medication for incident moderate-to-severe alcohol use disorder.The American journal on addictions · 2025Article
- Exploring the impact of a medication adherence intervention on recovery and mental health outcomes: A secondary analysis of the MAT-PLUS pilot RCT.Drug and alcohol dependence reports · 2025Article
- Predictors of Treatment Adherence in a Randomized Clinical Trial of Digital Therapeutics with Pharmacology for Alcohol Use Disorder (AUD).Journal of clinical trials · 2025Article
- A preliminary randomized trial of the safety, tolerability, and clinical effects of hemp-derived cannabidiol in alcohol use disorder.Frontiers in psychiatry · 2025Article
- Oxytocin as a treatment for alcohol use disorder and heavy drinking: A narrative review.Experimental and clinical psychopharmacology · 2024Review
- Patterns of publicly funded naltrexone use among patients diagnosed with alcohol use disorder in Ontario.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Article
- Gut-Liver-Brain Axis and Alcohol Use Disorder: Treatment Potential of Fecal Microbiota Transplantation.Alcohol research : current reviews · 2024Review
- The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder.Current medicinal chemistry · 2024Review
- Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.Clinical therapeutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveU.S. Food and Drug Administration (FDA)-approved medications exist for the treatment of alcohol use disorders. However, their effectiveness depends on proper adherence to the prescribed regimen. Differences in adherence across medications may have implications for clinical outcomes and may provide helpful information in considering treatment options. This study aims to identify significant differences in adherence if present.
methodA retrospective chart review was conducted in the Veterans Integrated Service Networks (VISN)-7 region of Veterans Affairs hospital and community-based outpatient clinics within South Carolina and Georgia. Prescriptions of FDA-approved alcohol use disorder medications from 2010 through 2015 were reviewed. Adherence was determined by the proportion of days the veteran had oral or injectable medication available over a 6-month period as noted by medication fills (reported as 0%-100% medication availability). We compared adherence for specific medications using chi-square, t test, logistic regression for dichotomous outcomes, and linear regression for continuous outcomes.
resultsA total of 715 subjects and 807 medication trials were included. Mean adherence (percentage of days that medication was available) was 41.3% for disulfiram, 44.7% for acamprosate, 49.8% for oral naltrexone, and 54.6% for extended-release injectable naltrexone. The mean adherence was significantly different between disulfiram and oral naltrexone (p = .002) as well as disulfiram and extended-release injectable naltrexone (p = .004). Adherence of 80% was achieved in 11.9%, 19.4%, 22.7%, and 24.4% of treatment courses with disulfiram, acamprosate, naltrexone, and extended-release injectable naltrexone, respectively. These differences were significant for disulfiram versus oral naltrexone (p = .004) and disulfiram versus extended-release injectable naltrexone (p = .05).
conclusionsThese results demonstrate that overall adherence to medication-assisted treatment for alcohol use disorder is low across all medications. When directly compared, disulfiram had significantly lower adherence than both oral and extended-release injectable naltrexone.
Indexed as
Identifiers
31603760PMC6811722W2981001303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.